Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:32:32.645Z.
Calculation as of: 2026-10-06T16:32:32.645Z.
Quote observation: 2026-10-06T16:30:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26a6c2e450689c32f4e4e5954cf906f309ed45562a8b136dc87c806878a45fac
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$5.91B
EBITDA Yield
2.24%
TTM Avg
1.62%
3Y Avg
2.24%
5Y Avg
4.65%
Market Cap
$5.74B
EBITDA Yield
1.83%
TTM Avg
1.65%
3Y Avg
1.60%
5Y Avg
1.99%
Market Cap
$5.53B
EBITDA Yield
3.25%
TTM Avg
3.04%
3Y Avg
3.04%
5Y Avg
3.04%
Market Cap
$6.51B
EBITDA Yield
5.89%
TTM Avg
7.53%
3Y Avg
7.75%
5Y Avg
5.52%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $6.01B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 2.24% | 1.62% | 2.24% | 4.65% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.90B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 1.83% | 1.65% | 1.60% | 1.99% |
| CG Oncology Inc. (CGON)vs › | $5.68B | N/A | N/A | N/A | N/A |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.33B | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.53B | 3.25% | 3.04% | 3.04% | 3.04% |
| RadNet, Inc. (RDNT)vs › | $5.52B | 4.61% | 4.21% | 4.87% | 6.47% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 5.89% | 7.53% | 7.75% | 5.52% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.52B | 6.51% | 7.99% | 9.42% | 8.85% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
